CSIMarket
 
Mind Medicine mindmed Inc   (MNMD)
Other Ticker:  
 
 
Price: $9.9100 $0.74 8.070%
Day's High: $10.03 Week Perf: 26.08 %
Day's Low: $ 8.83 30 Day Perf: 116.38 %
Volume (M): 3,048 52 Wk High: $ 11.10
Volume (M$): $ 30,208 52 Wk Avg: $3.83
Open: $9.24 52 Wk Low: $2.41



 Market Capitalization (Millions $) 394
 Shares Outstanding (Millions) 40
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -77
 Cash Flow (TTM) (Millions $) -37
 Capital Exp. (TTM) (Millions $) 0

Mind Medicine Mindmed Inc
Mind Medicine (MindMed) Inc. is a biotechnology company that focuses on the development of psychedelic medicines. They aim to address mental health disorders and addiction through innovative therapeutic approaches. MindMed is researching and developing psychedelic substances like psilocybin, LSD, and MDMA for use in therapeutic settings. By harnessing the potential of these substances, they hope to provide effective and alternative treatments for various mental health conditions. Their goal is to revolutionize the field of psychiatry and improve the lives of individuals suffering from these disorders.


   Company Address: One World Trade Center New York 10007 NY
   Company Phone Number: 220-6633   Stock Exchange / Ticker: NASDAQ MNMD
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Transactions

MindMed Announces Pricing of Underwritten Offering and Concurrent Private Placement for Promising Brain Health Treatments

Published Thu, Mar 7 2024 12:13 PM UTC



Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company specializing in the development of groundbreaking therapies for brain health disorders, has made an important announcement regarding the pricing of an underwritten offering of common shares and a concurrent private placement. This strategic move aims to strengthen the company's financial posit...

Product Service News

FDA Grants Breakthrough Therapy Designation to MindMed's MM120 for Generalized Anxiety Disorder, with Positive 12-Week Durability Data From Phase 2B Study

Published Thu, Mar 7 2024 11:00 AM UTC

MindMed, a renowned clinical stage biopharmaceutical company specializing in the development of innovative treatments for brain health disorders, has achieved a significant milestone with the recent FDA breakthrough therapy designation granted to its MM120 program. This designation is a testament to the potential of MM120 (lysergide d-tartrate) in the treatment of generalize...

Product Service News

MindMed Set to Share Promising Updates on MM120 for Generalized Anxiety Disorder

Published Fri, Mar 1 2024 2:00 PM UTC

On March 7, 2024, Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, will hold an eagerly anticipated conference call and webcast. The company aims to provide a comprehensive update on MM120, its innovative product candidate targeting Generalized Anxiety Disorder (GAD). This announcement follows the completion of MindMed's Phase 2b trial and promises t...

Business Update

MindMed Reports Positive Financial Results and Sees Promising Outlook for 2024

Published Wed, Feb 28 2024 12:05 PM UTC

MindMed Reports Positive Financial Results and Promising Business Updates for 2023Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company dedicated to developing innovative treatments for brain health disorders, has recently unveiled its financial outcomes for the year ending December 31, 2023, along with a comprehensive business update. The company's impres...

Business Update

MindMed to Discuss 2023 Financial Results and Business Update in Conference Call and Webcast

Published Thu, Feb 22 2024 12:00 PM UTC

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company focused on developing innovative therapies for brain health disorders, has announced plans to host a conference call and webcast on February 28, 2024. The event aims to provide a corporate update and review the company's financial results for the year ended December 31, 2023.Conference Call DetailsSet t...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com